Danner, S.A.

patient monotherapy protease inhibitor therapy haart mutation failure study lpv /r monotherapy hiv-rna trial virologic failure resistance virologic lpv /r protease inhibitor mutations protease inhibitor monotherapy lopinavir ef ficacy antiretroviral ritonavir-boosted therapy failure treatment suppression hiv -2-infected patients 50 copies /ml regimen antiretroviral therapy /ritonavir analysis infection as-treated analysis plasma follow-up month maintenance conference result lopinavir /ritonavir european aids conference combination hiv -2 ficacy -2-infected randomized hiv -2 consensus 48 weeks protease inhibitors bierman group wilkin pi mutations virus william protease inhibitor mutation sample fi ve patients lpv /r haart lippincott atv /r monotherapy as-treated hiv infection protease inhibitor article reproduction fication copyright induction nnrti intent-to-treat analysis 24 weeks 2007. van der ende maintenance therapy <50 500 copies /ml protease inhibitor resistance table group i group ii